ACTL6A suppresses p21<sup>Cip1</sup> expression to enhance the epidermal squamous cell carcinoma phenotype

Suruchi Shrestha<sup>1</sup>, Gautam Adhikary<sup>1</sup>, Wen Xu<sup>1</sup>, Sivaveera Kandasamy<sup>5</sup>, Richard L. Eckert<sup>1,2,3,4</sup>

<sup>1</sup>Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland; <sup>2</sup>Department of Dermatology, University of Maryland School of Medicine, Baltimore, Maryland; <sup>3</sup>Department of Reproductive Biology, University of Maryland School of Medicine, Baltimore, Maryland; <sup>4</sup>Department of Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland; <sup>5</sup>Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.

Abstract

Epidermal squamous cell carcinoma (SCC) is a common and highly invasive form of cancer. SCC arises due to ultraviolet light exposure and is associated with increased expression of pro-cancer genes and reduced expression of cancer suppressors. Actin-Like Protein 6A (ACTL6A, BAF53a) is an important protein subunit of the SWI/SNF epigenetic chromatin regulatory complex. ACTL6A is elevated in cancer cells and has been implicated as a driver of cancer cell proliferation and tumor growth. In the present study, we show that ACTL6A drives SCC cell proliferation, spheroid formation, invasion and migration, and that these activities are markedly reduced by ACTL6A knockdown. We further show that ACTL6A expression is associated with reduced levels of the p21<sup>Cip1</sup> cyclin-dependent kinase inhibitor and tumor suppressor protein. Molecular studies show that ACTL6A interacts with p53 DNA response elements in the p21<sup>Cip1</sup> gene promoter to suppress p21<sup>Cip1</sup> promoter activity and mRNA and protein level. Additional studies show that an increase in p21<sup>Cip1</sup> expression in ACTL6A knockdown cells is required for suppression of the SCC cell phenotype, suggesting that p21<sup>Cip1</sup> is a mediator of ACTL6A action. We further show that this regulation is p53 independent. These findings suggest that ACTL6A suppresses p21<sup>Cip1</sup> promoter activity to reduce p21<sup>Cip1</sup> protein as a mechanism to maintain the aggressive epidermal squamous cell carcinoma phenotype.
Keywords

ACTL6A; SWI/SNF complex; BAF53A; p21Cip1; p53; cancer stem cells; epidermal squamous cell carcinoma

Introduction

Epidermal squamous cell carcinoma (SCC) is among the most common cancers [1, 2]. SCC is treated by surgical excision, but the recurrence and metastatic rates still approach 10% [2]. Because this is a common cancer there are many cases of recurrent therapy-resistant cancer. It is thought that this involves expansion of epidermal cancer stem cells to form rapidly growing, aggressive and invasive tumors [3–5]. Treatment of these cancers has not been successful [6] and so identification of new targets is a major goal.

The SWI/SNF epigenetic regulatory complex controls nucleosome phasing, chromatin remodeling and transcription [7, 8]. The SWI/SNF complex is a large multi-subunit complex that generally acts as a tumor suppressor; however, protein subunits of this complex are frequently mutated or lost in tumors creating conditions that are permissive for cancer development [7]. BAF47, for example, is often lost/mutated in malignant rhabdoid cancer [7] and the Brg1 and Brm proteins, which comprise the catalytic subunits of the SWI/SNF complex, are lost in various cancer cell types [9]. ACTL6A (Actin-Like Protein 6A) is a protein that interacts with the SWI/SNF complex to activate the Brg1 ATPase [10]. However, ACTL6A also acts independent of the SWI/SNF complex to enhance cancer cell survival [11–14]. ACTL6A maintains epidermal stem cell self-renewal to prevent differentiation [15], serves as a c-myc cofactor in cancer stem cells where it acts as an oncogenic driver [16] and is associated with epithelial-mesenchymal transition and metastasis [17–19]. Moreover, ACTL6A overexpression predicts a poor prognosis [19].

ACTL6A has been reported to stabilize the YAP1/TAZ pro-cancer transcriptional regulators [20, 21], and to suppress expression of the p21Cip1 tumor suppressor [22–24]. We were interested to understand the role of ACTL6A in epidermal squamous cell carcinoma, as YAP1/TAZ [25, 26] and p53/p21Cip1 signaling [27–29] regulate the cancer phenotype. In the present study, we show that ACTL6A enhances the SCC cancer cell phenotype by interacting with and suppressing p21Cip1 promoter activity to reduce p21Cip1 mRNA and protein. We further confirm that ACTL6A suppression of p21Cip1 level is required for optimal cancer cell proliferation, spheroid formation, invasion, migration and tumor formation. Our findings support a model where ACTL6A interacts with the p53 response elements in the p21Cip1 promoter to reduce expression via a p53-independent mechanism, and that loss of p21Cip1 tumor suppressor enhances the epidermal squamous cell carcinoma phenotype.

Results

**ACTL6A maintains p21Cip1 level to suppress the cancer cell phenotype**

We initiated this study, by examining the impact of suppressing ACTL6A function on cell proliferation, spheroid formation, invasion and migration. Enhanced spheroid formation,
invasion and migration are phenotypic hallmarks of aggressive epidermal cancer cells [3, 25, 26, 30]. Fig. 1A shows the successful knockdown of ACTL6A. Fig. 1B/C/D/E show that ACTL6A loss is associated with reduced SCC-13 cell proliferation, spheroid formation, invasion and migration. To understand how ACTL6A enhances the ECS cell phenotype, we assessed the impact of ACTL6A loss on apoptosis and on p21Cip1 cyclin-dependent kinase inhibitor level. Fig. 1F shows that ACTL6A knockdown does not alter procaspase or PARP level, suggesting that ACTL6A does not maintain the pro-cancer phenotype by suppressing apoptosis. In contrast, ACTL6A loss results in a substantial increase in p21Cip1 (Fig. 1G), suggesting a possible role for p21Cip1. As a complementary approach to study the relationship between ACTL6A and p21Cip1, we created ACTL6A knockout cell lines and examined the impact on p21Cip1 expression and the cancer phenotype. Fig. 1H confirms ACTL6A loss in each of three clonal ACTL6A knockout cell lines. Fig. 1I/J/K confirms that this is associated with increased p21Cip1 expression and shows that stable ACTL6A loss reduces cancer cell proliferation, spheroid formation and invasion.

**p21Cip1 regulates the ECS cell phenotype**

Fig. 1G suggests that ACTL6A may suppress p21Cip1 to drive the ECS cell phenotype. To assess the role of p21Cip1 as a mediator of ACTL6A action, we performed p21Cip1 knockdown experiments. Fig. 2A shows that p21Cip1 knockdown does not alter ACTL6A level, suggesting that p21Cip1 is a downstream target of ACTL6A. Figs. 2B/C show that loss of p21Cip1 increases cell invasion and migration. We next treated ACTL6A knockout cells, which express elevated levels of p21Cip1, with p21Cip1-siRNA and monitored the impact on invasion and migration. Fig. 2D shows the successful knockdown of p21Cip1 and Fig. 2E/F show that reducing p21Cip1 level restores cell invasion and migration. These findings confirm that ACTL6A suppresses p21Cip1 level as a mechanism to enhance the cancer cell phenotype.

**ACTL6A regulates p21Cip1 promoter activity**

We next examined the mechanism responsible for increased p21Cip1 in ACTL6A knockdown cells by studying the impact of ACTL6A on p21Cip1 mRNA level and promoter activity. Fig. 2G/H shows an increase in p21Cip1 protein and mRNA level following ACTL6A knockdown. To determine if this RNA increase is due to transcriptional regulation, we measured the impact of ACTL6A loss on the activity of p21–2326 Luc, which encodes the full-length p21Cip1 gene promoter fused to the luciferase reporter gene. Fig. 2I shows that ACTL6A loss results in increased p21Cip1 promoter activity. Fig. 2J shows a map of the p21Cip1 promoter, identifying the position of the p53 (p53-1 and p53-2) cis-acting DNA binding elements, that are important mediators of p21Cip1 transcription activation and the canonical Sp1 response region (Sp1) which encodes six Sp1 response elements [28, 31]. To determine if the p53 sites are required for ACTL6A regulation of p21Cip1 in SCC cells, we measured the impact of ACTL6A loss on activity of wild-type and p53 site-mutant p21Cip1 reporter constructs. Loss of ACTL6A results in a substantial increase in luciferase activity for p21–2326 and p21–2326 (p53–Δ2), but not for p21–2326 (p53–Δ1) or p21–2326 (p53–Δ1/Δ2), suggesting that the p53-1 site is required for ACTL6A suppression of p21Cip1 promoter activity (Fig. 2K). Consistent with a role for ACTL6A in suppressing p21Cip1 promoter...

_Oncogene. Author manuscript; available in PMC 2021 January 02._
activity, we demonstrate that p21\textsuperscript{Cip1} promoter activity is increased in ACTL6A stable knockout cells (Fig. 2L).

**p53 does not mediate ACTL6A action**

p53 is known to bind the p21\textsuperscript{Cip1} promoter to activate transcription [29, 31]. To determine if ACTL6A suppresses p53 level to reduce p21\textsuperscript{Cip1}, we treated SCC-13 cells with control- or ACTL6A-siRNA and monitored the impact on p53 expression. As shown in Fig. 3A/B, loss of ACTL6A increases p53 mRNA and protein, and this is associated with increased p21\textsuperscript{Cip1} level suggesting that p53 may drive p21\textsuperscript{Cip1} expression in ACTL6A knockdown cells. Moreover, ACTL6A/p53 coprecipitation (Fig. 3C) suggests a cooperative mechanism of action. If p53 drives p21\textsuperscript{Cip1} expression, we would anticipate that interfering with p53 function in ACTL6A knockdown cells would attenuate the increase in p21\textsuperscript{Cip1}. The ACTL6A-siRNA/p53-siRNA lane in Fig. 3D shows that suppressing the p53 increase in response to ACTL6A knockdown does not attenuate the increase in p21\textsuperscript{Cip1}. Moreover, suppressing p53 does not attenuate the increase in p21\textsuperscript{Cip1} promoter activity, the decrease in cell proliferation or the decrease in invasion and migration (Fig. 3E/F/G/H) observed in ACTL6A knockdown cells. These findings suggest that p53 does not regulate p21\textsuperscript{Cip1} level or the cancer phenotype. To gain additional insight, we measured ACTL6A and p53 interaction at the p21\textsuperscript{Cip1} promoter proximal region (which encodes six Sp1 sites) and at the p53-1 and p53-2 binding sites. We identified ACTL6A binding at the p53-1 and p53-2 sites, and at the proximal promoter, but no p53 interaction on these elements (Fig. 3I). The lack of p53 binding at these sites is consistent with the lack of p53 impact on cancer cell endpoints. This lack of a role for p53 likely relates to the fact that SCC-13 cells express a mutant inactive form of p53 [32].

**Role of ACTL6A in HaCaT cells**

To assess the role of ACTL6A in a second model system, we used HaCaT cells, an immortalized cell line derived from epidermis [33]. Fig. 4A shows that ACTL6A knockdown increases p53 and p21\textsuperscript{Cip1} in HaCaT cells, and Fig. 4B/C show that ACTL6A loss is associated with reduced spheroid formation (number and size) and migration, suggesting that ACTL6 functions to maintain the HaCaT cell cancer phenotype. We further show (Fig. 4D) that loss of ACTL6A increases p21\textsuperscript{Cip1} promoter activity and that mutation of the p53 binding sites attenuates the increase in promoter activity. To assess the role of p53 in regulating the HaCaT cell phenotype, we compared the impact of ACTL6A and p53 knockdown in HaCaT cells. Fig. 4E shows that ACTL6A knockdown, or simultaneous knockdown of ACTL6A and p53 leads to increased p21\textsuperscript{Cip1} and reduced HaCaT cell migration. In contrast, p53 knockdown did not impact either endpoint. Moreover, ChIP analysis revealed interaction of ACTL6A at the p21\textsuperscript{Cip1} promoter proximal Sp1 region and p53 binding sites. In contrast, p53 binding is not observed (Fig. 4F). These findings suggest that p53 does not modulate ACTL6A regulation of p21\textsuperscript{Cip1} or the cancer phenotype.

**Role of ACTL6A in tumor formation**

To study the role of ACTL6A in tumor formation, we examined the ability of spheroid-derived wild-type and ACTL6A null cells to form tumors in immune-compromised mice. We show results from two specific ACTL6A knockout cell lines, SCC-13-ACTL6A-
KOc1-10-4 and SCC-13-ACTL6A-KOc1-10-3. Fig. 5A shows that SCC-13-ACTL6A-KOc1-10-4 cells display reduced tumor growth. Fig. 5B shows that loss of ACTL6A is associated with increased p53 and p21\(^{Cip1}\), a result that is consistent with the findings from cultured cells. In addition, Fig. 5C show that apoptosis is slightly increased in the ACTL6A null tumors as evidenced by increased presence of cleaved caspase 8 and 9 and cleaved PARP. Similar results were observed in SCC-13-ACTL6A-KOc-1-10-3 cells. Fig. 5D shows a marked reduction in SCC-13-ACTL6A-KOc-1-10-3 cell tumor formation compared to SCC-13 cells, and Fig. 5E/F show that this is associated with increased expression of p53 and p21\(^{Cip1}\), and enhanced caspase 3 cleavage.

**Discussion**

**ACTL6A enhances the SCC cell cancer phenotype**

ACTL6A has been implicated in regulation of neural progenitor cell proliferation and differentiation [34, 35], maintenance of a stem-like state in epidermal keratinocytes [15] and regulation of EMT, invasion and migration in osteosarcoma and hepatocellular carcinoma [17, 19]. In the present study, we show that transient ACTL6A knockdown reduces SCC cell proliferation, spheroid formation, invasion and migration. These findings were confirmed using multiple clonal ACTL6A knockout cell lines. Biochemical analysis shows that loss of ACTL6A does not promote apoptosis, suggesting that enhanced apoptotic cell death is not a cause of the attenuated cancer phenotype. However, ACTL6A knockdown does result in a marked increase in p21\(^{Cip1}\), suggesting that this cyclin-dependent kinase inhibitor/tumor suppressor may be a downstream target that mediates ACTL6A suppression of the cancer cell phenotype. To test this, we monitored the impact of p21\(^{Cip1}\) knockdown on cancer cell properties. These studies show that p21\(^{Cip1}\) loss results in increased cancer cell invasion and migration. In addition, ACTL6A knockout cell lines express increased levels of p21\(^{Cip1}\) and display reduced invasion and migration. Knockdown of p21\(^{Cip1}\) in these cell clones resulted in increased cell invasion and migration. Taken together, these findings confirm that the increase in p21\(^{Cip1}\) in ACTL6A negative cells attenuates the cancer phenotype, and that p21\(^{Cip1}\) is a biologically important downstream mediator of ACTL6A action.

**ACTL6A regulates p21\(^{Cip1}\) gene transcription**

Our studies show that p21\(^{Cip1}\) level is increased in ACTL6A knockdown cells, and that the increased p21\(^{Cip1}\) level is associated with increased p21\(^{Cip1}\) mRNA and p21\(^{Cip1}\) gene promoter activity, suggesting transcriptional regulation. ACTL6A loss is also associated with increased p53 levels suggesting that p53, a known positive regulator of p21\(^{Cip1}\) expression [36], may be driving p21\(^{Cip1}\) gene expression in ACTL6A deficient cells. Further analysis reveals that the p53-1 and/or p53-2 DNA binding sites in the p21\(^{Cip1}\) promoter are required for increased promoter activity in ACTL6A knockdown or knockout cells and that mutation of these sites eliminates the increase. These studies strongly suggest a role for p53; however, suppression of the p53 increase observed in ACTL6A knockdown cells does not attenuate the increase in p21\(^{Cip1}\). Moreover, modulating p53 level did not attenuate the reduction in cell proliferation, invasion or migration observed in ACTL6A deficient cells. These findings suggest that although ACTL6A interacts with p53 and regulates p53 mRNA and protein level, p53 is not involved as a regulator of p21\(^{Cip1}\) expression. Our finding contrasts with a
study showing that ACTL6A reduces p21<sup>Cip1</sup> level by interacting with p53 to increase p53 acetylation leading to reduced p53 binding to the p21<sup>Cip1</sup> promoter and reduced promoter activity [22]. Our finding that ACTL6A regulation of p21<sup>Cip1</sup> expression does not involve p53 is likely because of the presence of mutant p53. In SCC-13 cells p53 glutamate 258 is mutated to lysine (E258K) [32] and in HaCaT cells p53 histidine 179 is mutated to tyrosine (H179Y) and arginine 282 is mutated to tryptophan (R282W) [37]. These p53 DNA binding domain mutations appear to prohibit interaction of these mutants with the p53 response elements. This likely explains why SCC-13 and HaCaT cell-derived p53 do not bind to the p21<sup>Cip1</sup> promoter p53 response elements, and why manipulating p53 level does not modulate ACTL6A regulation of p21<sup>Cip1</sup> expression in these cells.

The above findings suggest that ACTL6A acts alone (i.e., without p53), or acts with presently unknown partners, to suppress p21<sup>Cip1</sup> gene expression. It is possible that other p53 family members, such as ΔNp63α, which are known to regulate p21<sup>Cip1</sup> expression, may have a role [38]. Identifying co-regulators that act with ACTL6A will require further study.

**ACTL6A regulation of tumor formation**

To assess the in vivo relevance of these findings, we tested the impact of ACTL6A knockout on tumor formation. An epidermal cancer stem cell (ECS cells) enriched population [3], derived from spheroid cultures of SCC-13 wild-type cells and ACTL6A knockout clones, were injected into immunocompromised mice to monitor the impact of ACTL6A loss on tumor formation. These were selected because they display a highly aggressive phenotype [3]. We observe a dramatic reduction in tumor size for ACTL6A knockout cells. Biochemical analysis of tumor extracts confirms ACTL6A knockout and shows that this is associated with increased levels of p53 and p21<sup>Cip1</sup>. A modest increase in apoptosis is also observed. Thus, in both tumors and cultured cells, ACTL6A loss results in increased p21<sup>Cip1</sup> levels and this is associated with an attenuated cancer phenotype. The only difference we observe is that ACTL6A loss promotes a modest increase in apoptosis in tumors but not in cultured cells, a finding that could be expected considering the difference in the cell culture versus tumor environment. As apoptosis is only minimally increased in ACTL6A knockout tumors, it is not likely that this is a major cause of reduced tumor growth. The tumor findings are interesting in that the we have previously shown that spheroid-derived cells are enriched for highly aggressive cells that have cancer stem cell properties [3]. The fact that ACTL6A knockout dramatically reduces growth of these tumors argues that ACTL6A has an important role in maintaining the cancer stem cell population. This result is consistent with the reduction in the size of the cancer stem cell-enriched spheroids [3] following ACTL6A knockdown or knockout (Fig. 1K and Fig. 4B).

**ACTL6A function in epidermal squamous cell carcinoma**

Our findings indicate that ACTL6A loss in epidermal squamous cell carcinoma results in increased transcription of p21<sup>Cip1</sup> which leads to reduced cancer cell proliferation, spheroid formation, invasion, migration and tumor formation. Moreover, knockdown of p21<sup>Cip1</sup>, in the context of ACTL6A knockout, reduces the response to ACTL6A loss suggesting that p21<sup>Cip1</sup> is a biologically relevant mediator of ACTL6A action. This suggests that ACTL6A
interacts at the p21\textsuperscript{Cip1} promoter p53 consensus binding sites (p53-1, p53-2) to suppress p21\textsuperscript{Cip1} gene transcription (Fig. 5G). ACTL6A binding to these elements most likely requires other factors, but our studies suggest that p53 is not involved. We note that ACTL6A is also enriched at the proximal promoter region that encodes six Sp1 sites that are known to be involved in regulation of p21\textsuperscript{Cip1} gene expression [31]. This suggests that the proximal promoter may also be involved in ACTL6A regulation of p21\textsuperscript{Cip1}. Additional studies will be necessary to assess this possibility. Our findings support the concept that ACTL6A suppresses p21\textsuperscript{Cip1} transcription to reduce p21\textsuperscript{Cip1} mRNA and protein level and that this results in enhanced cancer cell proliferation, spheroid formation, invasion, migration and tumor formation.

Materials and Methods

Reagents

Rabbit anti-ACTL6A (A301–391A) was obtained from Bethyl Laboratories (Montgomery, TX). Rabbit antibodies specific for p53 (9282), p21\textsuperscript{Cip1} (2947), Caspase-9 (NB100–56708), cleaved PARP (556494), caspase-8 (9746) and ChIP grade IgG (2792) were obtained from Cell Signaling Technologies (Danvers, MA). Rabbit anti-caspase-3 (NB100–56708) was obtained from Novus Biologicals (Centennial, CO). Secondary rabbit IgG for immunoprecipitation (NI01) was obtained from Millipore/Sigma (St. Louis, MO). Control (sc-37007), p53 (sc-44218) and p21\textsuperscript{Cip1} (sc-29427) siRNA were obtained from Santa Cruz Biotechnology (Dallas, TX). ACTL6A-siRNA (AM16708) was obtained from Ambion (Philadelphia, PA). The Students t-test was used for statistical analysis. Assays were completed in triplicate and single and double asterisks indicate, respectively, a significant reduction and increase (p < 0.005) in response. Five animals per group was selected to give a statistically meaningful outcome based on experience and no animals were excluded from analysis.

Cell culture

SCC-13 are human epidermis derived, tumor forming, squamous cell carcinoma cells [39]. HaCaT cells are immortalized cells derived from human epidermis that do not form tumors [40]. Cells were maintained in growth medium contained DMEM supplemented with 4.5 mg/ml D-glucose, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 U/ml streptomycin and 5 % fetal calf serum. To monitor cell proliferation, 20,000 cells were plated into 35 mm plates in triplicate in growth medium and cell number was monitored from 0 – 3 d. To assay spheroid formation, cells maintained in growth medium were harvested, resuspended in spheroid medium [DMEM/F12 (1:1) containing 2% B27 serum-free supplement, 20 ng/ml EGF, 0.4% bovine serum albumin and 4 mg/ml insulin] and plated at 40,000 cells per 35 mm ultra-low attachment dish [30, 41]. For cell invasion assay, 25,000 cells were plated into Millicell (1 cm diameter, 8 mm pore-size) chambers (353097) atop a 100 μl layer of 300 μg/ml matrigel (354234) [42]. Millicell chambers and matrigel were purchased from BD Biosciences (San Diego, CA). Growth medium containing 1% FCS (top chamber) or 10% FCS (bottom chamber) was added and the ability of cells to pass through the membrane was monitored over 0 – 18 h. The membrane was then fixed with 4% paraformaldehyde and stained with DAPI (D9542, Sigma Aldrich, Milwaukee, WI) and
nuclei of the invading cells were detected by fluorescence microscopy [42]. For migration assay, scratch wounds were created in confluent monolayer cultures of cells using a pipette tip and closure of the wound was monitored from 0 – 24 h.

Electroporation

Cells (1.2 million) were suspended in 100 μl of nucleofection reagent (VPD-1002, Lonza, Williamsport, PA) containing 3 μg of control- or target specific-siRNA and electroporated using the T-018 setting on an AMAXA Electroporator [43]. Pre-warmed growth medium (4 ml) was added and the cells were plated for 48 h in a 60 mm dish. The electroporation was then repeated, and after overnight recovery, the cells were plated to study spheroid formation, invasion and migration [30, 41].

Promoter activity assay

To measure the impact of ACTL6A on p21\textsuperscript{Cip1} promoter activity, cells were double-electroporated with 3 μg control- or ACTL6A-siRNA and plated onto 12 well plates in duplicate. The cells were permitted to attach overnight and then 1 μg reporter plasmid was mixed with 3 μl of Fugene-6 for transfection [31]. The p21\textsuperscript{Cip1} promoter reporter constructs were cloned in pBluescript-Luc (empty vector, EV) as p21–2326, p21–2326 (Δp53-1), p21–2326 (Δp53-2) and p21–2326 (Δp53-1/2). At 24 – 48 h, post-transfection, extracts were prepared for luciferase activity assay. p21–2326, which encodes the intact full length p21\textsuperscript{Cip1} promoter fused to luciferase, was provided by Dr. Bert Vogelstein [44]. The p21\textsuperscript{Cip1} p53 binding site mutant promoter constructs were previously described [31].

Immunological methods

An equivalent amount of protein was electrophoresed on denaturing and reducing 10% polyacrylamide gels and transferred to nitrocellulose. The membrane was blocked by 5% non-fat dry milk and then incubated with appropriate primary and secondary antibody. Antibody binding was visualized using chemiluminescence detection reagents [31]. For immunoprecipitation, 200 μg of protein was incubated with 1 μg antibody overnight at 4°C. Washed Pierce Protein A/G agarose (20421, Thermo Scientific, Frederick, MD) was added after 18 h and incubated at 4°C for 4 h. After washing, the beads were boiled in SDS buffer and aliquots were electrophoresed on denaturing and reducing polyacrylamide gels [31].

Chromatin immunoprecipitation (ChIP)

ChIP was performed as described in the Diagenode LowCell\# ChIP kit (kch-maglow-G48, Diagenode, Inc., Denville, NJ) protocol. Briefly, one million cells were trypsinized and washed with phosphate buffered saline containing 20 μM sodium butyrate. The cells were crosslinked with 1% formaldehyde at room temperature for 10 min followed by quenching with 125 nM glycine. Crosslinked cells were washed with phosphate buffered saline and lysed with Diagenode lysis buffer supplemented with 1 x protease inhibitor and 20 μM sodium butyrate. The samples were chilled on ice and DNA was sheared using a 550 Sonic Dismembrator (five 30 second pulses at 30% amplitude with 30 seconds between pulses) to obtain 200 – 1000 bp DNA fragments. The samples were diluted in Diagenode buffer containing 20 μM sodium butyrate and 1 x protease inhibitor. ChIP grade antibodies (1 μg)
were incubated with protein G coated magnetic beads for 3 h at 4°C and sheared chromatin (100,000 cells equivalent) was added to the beads and incubated overnight at 4°C. DNA was isolated from the samples the next day using Diagenode DNA isolation buffer with proteinase K. p21\textsuperscript{Cip1} promoter DNA were detected by qPCR using sequence specific primers and LightCycler 480 SYBR green I master mix. ChIP analysis of the p21\textsuperscript{Cip1} promoter included primers that target the proximal Sp1 elements (forward 5’-GCTGGGCAGCCAGGAGCCTG and reverse 5’-CTGCTCACACCTCAGCTGGC), the p53-1 site (forward 5’-GTGGGTCTGTATGGGCTTCTG and reverse 5’-CTGAAAAACGGCAGCCCAAG) and the p53-2 site (forward 5’-CCGAGGTCAGCTCGTTAGAGG and reverse 5’-AGAACCCAGGCTTGAGCAGC).

**ACTL6A knockout cells**

ACTL6A-specific CRISPR guide RNA, forward (5’-caccGGCGATAAAGGCAAACAAGG) and reverse (5’-aaacCCTTGTGTTGCCCTTATGCC), were identified using tools at [http://crispr.technology](http://crispr.technology) and cloned into the U6-driven pSpCas9(BB)-2A-Puro (PX459) V2.0 vector from Addgene. The vector (3 μg) was electroporated into SCC-13 cells using the AMAXA electroporator and at 48 h post-electroporation the cells were treated with 2 μg/ml puromycin for 24 h followed by selection of single cell clones by dilution cloning.

**qRT-PCR**

RNA was isolated using Illustra RNAspin Mini kit (25050070, GE Healthcare, Chicago, IL), reverse-transcribed and quantified using the LightCycler 480 PCR system (Roche Life Science, Branford, CT). Specific PCR primers were used to quantify the transcript level using LightCycler 480 SYBR Green I, and signals were normalized to cyclophilin A. The primers include p21\textsuperscript{Cip1} forward (5’-CGTCTGCAACCAGGGATTTCTT-3’) and reverse (5’-TGTTGATTGTCACATGCTTGGG-3’), and p53 forward (5’-TAACAGTTCTGTAGTGCAGTGG-3’) and reverse (5’-AGGACAGGCACAAACACGCACC-3’).

**Tumor xenografts**

Cells (200,000) were re-suspended in 200 μl of phosphate buffered saline containing 30% matrigel and 100 μl was injected subcutaneously into each front flank of five 8-week-old NOD/scid/IL2 receptor γ chain knockout mice (NSG) per treatment group. Tumor growth was monitored by measuring tumor diameter and calculating tumor volume = 4/3π \times (diameter/2)\textsuperscript{3}. Tumor samples were harvested to prepare extracts for immunoblot [45].

**Acknowledgements**

This work was supported by National Institutes of Health R01 grants CA184027 and CA211909 awarded to Richard L. Eckert, PhD.

**Abbreviations:**

- **ACTL6A** Actin-Like Protein 6A
- **SCC** epidermal squamous cell carcinoma
References

1. Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley CC, Weaver AL et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 2005; 294: 681–690. [PubMed: 16091570]

2. Moller R, Reymann F, Hou-Jensen K. Metastases in dermatological patients with squamous cell carcinoma. Arch Dermatol 1979; 115: 703–705. [PubMed: 453871]

3. Adhikary G, Grun D, Kerr C, Balasubramanian S, Horke EA, Vemuri M et al. Identification of a population of epidermal squamous cell carcinoma cells with enhanced potential for tumor formation. PLoS One 2013; 8: e84324. [PubMed: 24376802]

4. Fisher ML, Adhikary G, Xu W, Kerr C, Keillor JW, Eckert RL. Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition. Oncotarget 2015; 6: 20525–20539. [PubMed: 25971211]

5. Grun D, Adhikary G, Eckert RL. VEGF-A acts via neuropilin-1 to enhance epidermal cancer stem cell survival and formation of aggressive and highly vascularized tumors. Oncogene 2016; 35: 4379–4387. [PubMed: 26804163]

6. Cranmer LD, Engelhardt C, Morgan SS. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist 2010; 15: 1320–1328. [PubMed: 21147868]

7. Kadoch C, Crabtree GR. Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. Sci Adv 2015; 1: e1500447. [PubMed: 26601204]

8. St PR, Kadoch C. Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities. Curr Opin Genet Dev 2017; 42: 56–67. [PubMed: 28391084]

9. Reisman DN, Strobeck MW, Betz BL, Scarfotta JF, Funkhouser W Jr., Murchardt C et al. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene 2002; 21: 1196–1207. [PubMed: 11850839]

10. Zhao K, Wang W, Rando OJ, Yue Y, Swiderek K, Kuo A et al. Rapid and phosphoinositol-dependent binding of the SWI/SNF-like BAF complex to chromatin after T lymphocyte receptor signaling. Cell 1998; 95: 625–636. [PubMed: 9845365]

11. Krusteva V, Buscarlet M, Diaz-Tellez A, Barnard MA, Crabtree GR, Lessard JA. The BAF53a subunit of SWI/SNF-like BAF complexes is essential for hemopoietic stem cell function. Blood 2012; 120: 4720–4732. [PubMed: 23018638]

12. Lu W, Fang L, Ouyang B, Zhang X, Zhan S, Feng X et al. Actl6a protects embryonic stem cells from differentiating into primitive endotherm. Stem Cells 2015; 33: 1782–1793. [PubMed: 25802002]

13. Zhu B, Ueda A, Song X, Horike SI, Yokota T, Akagi T, Baf53a is involved in survival of mouse ES cells, which can be compensated by Baf53b. Sci Rep 2017; 7: 14059. [PubMed: 29070872]

14. Taulli R, Foglizzo V, Morena D, Codá DM, Ala U, Bersani F et al. Failure to downregulate the BAF53a subunit of the SWI/SNF chromatin remodeling complex contributes to the differentiation block in rhabdomyosarcoma. Oncogene 2014; 33: 2354–2362. [PubMed: 23728344]

15. Bao X, Tang J, Lopez-Pajares V, Tao S, Qu K, Crabtree GR et al. ACTL6a enforces the epidermal progenitor state by suppressing SWI/SNF-dependent induction of KLF4. Cell Stem Cell 2013; 12: 193–203. [PubMed: 23395444]

16. Park J, Wood MA, Cole MD. BAF53 forms distinct nuclear complexes and functions as a critical c-Myc-interacting nuclear cofactor for oncogenic transformation. Mol Cell Biol 2002; 22: 1307–1316. [PubMed: 11839798]

17. Xiao S, Chang RM, Yang MY, Lei X, Liu X, Gao WB et al. Actin-like 6A predicts poor prognosis of hepatocellular carcinoma and promotes metastasis and epithelial-mesenchymal transition. Hepatology 2016; 63: 1256–1271. [PubMed: 26698646]

18. Meng L, Wang X, Liao W, Liu J, Liao Y, He Q. BAF53a is a potential prognostic biomarker and promotes invasion and epithelial-mesenchymal transition of glioma cells. Oncol Rep 2017; 38: 3327–3334. [PubMed: 29039584]

Oncogene. Author manuscript; available in PMC 2021 January 02.
19. Sun W, Wang W, Lei J, Li H, Wu Y. Actin-like protein 6A is a novel prognostic indicator promoting invasion and metastasis in osteosarcoma. Oncol Rep 2017; 37: 2405–2417. [PubMed: 28260090]

20. Ji J, Xu R, Zhang X, Han M, Xu Y, Wei Y et al. Actin like-6A promotes glioma progression through stabilization of transcriptional regulators YAP/TAZ. Cell Death Dis 2018; 9: 517. [PubMed: 29725063]

21. Saladi SV, Ross K, Karayyavaz M, Tata PR, Mou H, Rajagopal J et al. ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis. Cancer Cell 2017; 31: 35–49. [PubMed: 28041841]

22. Wang M, Gu C, Qi T, Tang W, Wang L, Wang S et al. BAF53 interacts with p53 and functions in p53-mediated p21-gene transcription. J Biochem 2007; 142: 613–620. [PubMed: 17878219]

23. Lee JH, Chang SH, Shim JH, Lee JY, Yoshida M, Kwon H. Cytoplasmic localization and nucleocytoplasmic shuttling of BAF53, a component of chromatin-modifying complexes. Mol Cells 2003; 16: 78–83. [PubMed: 14503849]

24. Lee JH, Lee JY, Chang SH, Kang MJ, Kwon H. Effects of Ser2 and Tyr6 mutants of BAF53 on cell growth and p53-dependent transcription. Mol Cells 2005; 19: 289–293. [PubMed: 15879716]

25. Fisher ML, Ciavattone N, Grun D, Adhikary G, Eckert RL. Sulforaphane reduces YAP/Np63alpha signaling to reduce cancer stem cell survival and tumor formation. Oncotarget 2017; 8: 73407–73418. [PubMed: 29088716]

26. Fisher ML, Kerr C, Adhikary G, Grun D, Xu W, Keillor JW et al. Transglutaminase Interaction with alpha6/beta4-Integrin Stimulates YAP1-Dependent DeltaNp63alpha Stabilization and Leads to Enhanced Cancer Stem Cell Survival and Tumor Formation. Cancer Res 2016; 76: 7265–7276. [PubMed: 27780825]

27. Kerr C, Adhikary G, Grun D, George N, Eckert RL. Combination cisplatin and sulforaphane treatment reduces proliferation, invasion, and tumor formation in epidermal squamous cell carcinoma. Mol Carcinog 2018; 57: 3–11. [PubMed: 28796401]

28. Chew YC, Adhikary G, Wilson GM, Reece EA, Eckert RL. PKCd delta suppresses keratinocyte proliferation by increasing p21CIP1 level by a KLF4-dependent mechanism. J Biol Chem 2011; 286: 28771–28782.

29. Saha K, Adhikary G, Kanade SR, Rorke EA, Eckert RL. p38delta regulates p53 to control p21Cip1 expression in human epidermal keratinocytes. J Biol Chem 2014; 289: 11443–11453. [PubMed: 24599959]

30. Adhikary G, Grun D, Balasubramanian S, Kerr C, Huang JM, Eckert RL. Survival of skin cancer stem cells requires the Ezh2 polycomb group protein. Carcinogenesis 2015; 36: 800–810. [PubMed: 25969142]

31. Chew YC, Adhikary G, Wilson GM, Xu W, Eckert RL. Sulforaphane induction of p21(Cip1) cyclin-dependent kinase inhibitor expression requires p53 and Sp1 transcription factors and is p53-dependent. J Biol Chem 2012; 287: 16168–16178. [PubMed: 22427654]

32. Burns JE, Baird MC, Clark LJ, Burns PA, Edington K, Chapman K et al. Gene mutations and increased levels of p53 protein in human squamous cell carcinomas and their cell lines. Br J Cancer 1993; 67: 1274–1284. [PubMed: 8390283]

33. Boukamp P, Petrussevska RT, Breitkreutz D, Hormung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988; 106: 761–771. [PubMed: 2450098]

34. Lessard J, Wu JI, Ranish JA, Wan M, Winslow MM, Staalh BT et al. An essential switch in subunit composition of a chromatin remodeling complex during neural development. Neuron 2007; 55: 201–215. [PubMed: 17640523]

35. Ronan JL, Wu W, Crabtree GR. From neural development to cognition: unexpected roles for chromatin. Nat Rev Genet 2013; 14: 347–359. [PubMed: 23568486]

36. Le BR, Hoflack B. Protein transport from the secretary to the endocytic pathway in mammalian cells. Biochim Biophys Acta 1998; 1404: 195–209. [PubMed: 9714803]

37. Lehman TA, Modali R, Boukamp P, Stanek J, Bennett WP, Welsh JA et al. p53 mutations in human immortalized epithelial cell lines. Carcinogenesis 1993; 14: 833–839. [PubMed: 8504475]
38. Westfall MD, Mays DJ, Sniezek JC, Pietenpol JA. The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol 2003; 23: 2264–2276. [PubMed: 12640112]

39. Rheinwald JG, Beckett MA. Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultures from human squamous cell carcinomas. Cancer Res 1981; 41: 1657–1663. [PubMed: 7214336]

40. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988; 106: 761–771. [PubMed: 2450098]

41. Zirvi KA, Keogh JP, Slomiany A, Slomiany BL. Effects of exogenous transglutaminase on spreading of human colorectal carcinoma cells. Cancer Biochem Biophys 1993; 13: 283–294. [PubMed: 8521378]

42. Fisher ML, Keillor JW, Xu W, Eckert RL, Kerr C. Transglutaminase is required for epidermal squamous cell carcinoma stem cell survival. Mol Cancer Res 2015; 13: 1083–1094. [PubMed: 25934691]

43. Adhikary G, Chew YC, Reece EA, Eckert RL. PKC-delta and -eta, MEKK-1, MEK-6, MEK-3, and p38-delta Are Essential Mediators of the Response of Normal Human Epidermal Keratinocytes to Differentiating Agents. J Invest Dermatol 2010.

44. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–825. [PubMed: 8242752]

45. Adhikary G, Grun D, Alexander HR, Friedberg JS, Xu W, Keillor JW et al. Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation. Oncotarget 2018; 9: 34495–34505. [PubMed: 30349644]
ACTL6A knockdown attenuates the cancer cell phenotype. **A** Successful siRNA knockdown of ACTL6A. **B/C/D/E** ACTL6A knockdown reduces SCC-13 cell proliferation, spheroid formation, invasion and migration. **F** ACTL6A knockdown does not impact apoptosis marker levels. **G** ACTL6A knockdown results in increased p21Cip1 levels. **H/I/J/K** ACTL6A knockout cells display increased p21Cip1 level which is associated with reduced cell proliferation, invasion and spheroid formation.

*Oncogene. Author manuscript; available in PMC 2021 January 02.*
Fig. 2. p21Cip mediates ACTL6A action. A Successful siRNA knockdown of p21Cip with absence of impact on ACTL6A level. B/C p21Cip knockdown enhances invasion and migration. D Successful p21Cip knockdown in ACTL6A knockout cells. E/F p21Cip knockdown in ACTL6A-null cells enhances cell invasion and migration. G/H ACTL6A knockdown increases p21Cip protein and mRNA levels. I ACTL6A knockdown increases activity of the full-length p21Cip promoter. J p21Cip promoter map showing the full-length promoter (nucleotides −2326−1) including the proximal Sp1 response region, the two p53 response elements and the start of transcription (arrow). The sequence of the wild-type and mutant p53 elements are also shown. K The p53-1 site is required for the increase in p21Cip promoter activity in response to ACTL6A knockdown. L p21Cip promoter activity is elevated in ACTL6A-knockout cells lines as compare to wild-type cells.
Fig. 3.
p53 is not required for ACTL6A regulation of p21\textsuperscript{Cip1} level.

A/B  ACTL6A-knockdown results in increased p53 and p21\textsuperscript{Cip1} levels. C  p53/ACTL6A interaction is documented by co-precipitation following incubation of 200 μg cell lysate with 1 μg IgG or anti-p53 antibody and immunoblot with anti-ACTL6A.

D  ACTL6A knockdown increases p21\textsuperscript{Cip1} level, and this regulation was not impacted by manipulating p53 level.

E  ACTL6A knockdown increases p21\textsuperscript{Cip1} promoter activity but manipulating p53 level does not alter p21\textsuperscript{Cip1} promoter activity.

F/G/H  ACTL6A knockdown attenuates SCC-13 cell proliferation, invasion and migration, but these endpoints are minimally impacted by p53.

I  ChIP assay shows that ACTL6A, but not p53, interacts with the p21\textsuperscript{Cip1} proximal promoter Sp1 region and the p53 response elements.
Fig. 4. ACTL6A modulates p21\textsuperscript{Cip1} level to control the HaCaT phenotype. A ACTL6A knockdown results in increased p53 and p21\textsuperscript{Cip1} levels. B/C ACTL6A knockdown reduces HaCaT cell spheroid formation and migration. D ACTL6A knockdown results in increased p21\textsuperscript{Cip1} promoter activity and this increase requires both p53 binding elements (p53-1 and p53-2). E/F ACTL6A knockdown increases p21\textsuperscript{Cip1} level, but p53 knockdown does not influence p21\textsuperscript{Cip1} level. ACTL6A loss reduces cell migration, but migration is minimally impacted by p53 knockdown. G ChIP analysis shows that ACTL6A interacts at the proximal promoter Sp1 region and the p53 binding sites (p53-1 and p53-2), but that p53 does not bind at these sites.
Fig. 5.
ACTL6A knockout reduces tumor formation. A Spheroid-derived SCC-13 wild-type cells and SCC-13 ACTL6A knockout cell clones (SCC13-ACTL6A-KOc1-10-4 and SCC13-ACTL6A-KOc1-10-3) were injected into each front flank in NSG mice and tumor formation was monitored for 0 - 4 wk. 

A/B/C ACTL6A knockout cell (SCC13-ACTL6A-KOc1-10-4) tumor formation is reduced and this is associated with increased p53 and p21cip1 levels and minimal impact on apoptosis. 

D/E/F ACTL6A knockout cell (SCC13-ACTL6A-KOc1-10-3) tumor formation is reduced and this is associated with increased p53 and p21cip1 levels and activation of apoptosis. 

G Schematic describing the role of ACTL6A in regulating cancer cell function (details in text).